NMRA-215 / Neumora Therap - LARVOL DELTA

Neumora Therapeutics Highlights NMRA-511 AD Agitation Signal, Maps Higher-Dose Plan for 2026 (Yahoo Finance) - "Neumora plans a higher‑dose MAD cohort in 2026, pivotal studies in 2027, and a switch to a QD extended‑release formulation to extend IP to 2046...NMRA-215 (NLRP3 inhibitor) targets weight loss via sustained brain IC90 exposure and the company expects Q3 2026 biomarker data to show brain coverage and cardiometabolic effects, positioning the asset for GLP‑1 combination or maintenance strategies...Broader pipeline and timing: a mid‑2026 update is expected for the M4 PAMs, a combined readout for KOASTAL 2 & 3 is due in Q2 2026..."

Biomarker • Clinical data • New trial • Trial status • Alzheimer's Disease • Obesity

Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model (Neumora Press Release) - "NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction; NMRA-215 demonstrated best-in-class weight loss of up to 26% in combination with semaglutide; Class-leading weight loss driven by best-in-class pharmacology and brain penetration of NMRA-215; Neumora plans to initiate Phase 1 clinical study in the first quarter of 2026."

New P1 trial • Preclinical • Obesity